How Does Pfizer Stock Stack Up Against Its Peers?
Pfizer’s stock has underperformed some peers over the past year, as of February 25, 2026. How does it truly measure up against rivals navigating innovation and patent cliffs? A closer look reveals a moderate valuation (PE of 15.67), but below-average LTM revenue growth (3.9%) and profitability compared to industry leaders. The company faces significant headwinds from patent expirations expected to cause a $1.5 billion revenue headwind in 2026, rising to $4.5 billion in 2027, along with declining COVID-19 product sales. While Pfizer is investing in its pipeline, particularly in oncology and obesity through acquisitions like Metsera, visible pipeline offsets are not expected until 2028 or later, indicating a need for stronger catalysts to drive future upside.
- PFE’s 24.6% operating margin, lowest among peers (LLY at 45.6%), signals efficiency challenges or a less profitable product portfolio.
- PFE’s 3.9% revenue growth, trailing JNJ, ABBV, LLY but above MRK, BMY, suggests post-pandemic normalization impact or pipeline challenges.
- PFE’s 8.7% stock gain and 15.7 PE, below peers’ stronger returns, reflects investor skepticism regarding future growth or pipeline potential.
Here’s how Pfizer stacks up across size, valuation, and profitability versus key peers.
| PFE | JNJ | MRK | ABBV | LLY | BMY | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 154.0 | 590.3 | 305.5 | 401.4 | 921.6 | 124.7 |
| Revenue ($ Bil) | 62.8 | 94.2 | 64.2 | 61.2 | 65.2 | 48.2 |
| PE Ratio | 15.7 | 22.0 | 16.1 | 95.0 | 44.7 | 17.7 |
| LTM Revenue Growth | 3.9% | 6.0% | 1.7% | 8.6% | 44.7% | -0.2% |
| LTM Operating Margin | 24.6% | 27.2% | 34.9% | 32.8% | 45.6% | 28.5% |
| LTM FCF Margin | 16.5% | 20.5% | 20.3% | 29.1% | 9.2% | 26.7% |
| 12M Market Return | 8.7% | 51.7% | 39.0% | 14.9% | 14.9% | 10.6% |
For more details on Pfizer, read Buy or Sell PFE Stock. Below we compare PFE’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| PFE | 3.9% | – | 6.8% | -41.1% | 24.5% |
| JNJ | 6.0% | 6.0% | 4.3% | 6.5% | |
| MRK | 1.7% | – | 6.7% | 1.4% | 21.7% |
| ABBV | 8.6% | 8.6% | 3.7% | -6.4% | |
| LLY | 44.7% | 44.7% | 32.0% | 19.6% | |
| BMY | -0.2% | -0.2% | 7.3% | -2.5% |
Operating Margin Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| PFE | 24.6% | – | 23.3% | 7.1% | 36.7% |
| JNJ | 27.2% | 27.2% | 23.9% | 25.8% | |
| MRK | 34.9% | – | 31.5% | 4.9% | 30.8% |
| ABBV | 32.8% | 32.8% | 21.1% | 24.9% | |
| LLY | 45.6% | 45.6% | 37.8% | 30.3% | |
| BMY | 28.5% | 28.5% | 12.2% | 18.2% |
PE Ratio Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| PFE | 15.7 | – | 17.6 | 70.7 | 5.1 |
| JNJ | 22.0 | 18.6 | 24.8 | 11.3 | |
| MRK | 16.1 | – | 15.6 | 691.5 | 19.0 |
| ABBV | 95.0 | 95.6 | 73.5 | 56.3 | |
| LLY | 44.7 | 46.7 | 65.7 | 100.1 | |
| BMY | 17.7 | 15.6 | -12.8 | 13.2 |
Still not sure about PFE stock? Consider portfolio approach.
Portfolios Are The Smarter Way To Invest
Single stocks swing wildly but staying invested matters. A well built portfolio helps you stay invested, captures upside and softens the blows from individual stocks.
Why settle for average market returns? The Trefis High Quality (HQ) Portfolio invests in a diverse group of 30 stocks that have collectively delivered stronger upside with reduced volatility compared to the broader indices. Discover the methodology behind these smoother, higher returns by checking the HQ Portfolio performance data.